Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas Secures FDA Approval for First-in-Class PROTAC VEPPANU, Triggers $50M Milestone Payment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.27
Mkt Cap
$656.879M
52W Low
$5.9
52W High
$14.51
52W Position info
74% above low
Off High info
29% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ARVN sits 74% above its 52-week low of $5.9 on light trading volume (0.3× avg).

Summary

Arvinas announced FDA approval for VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for advanced breast cancer, triggering a $50 million milestone payment from Pfizer.


Key Events · Product Development and Regulatory · ARVN

  • FDA Approves VEPPANU

    The U.S. Food and Drug Administration (FDA) granted approval for VEPPANU (vepdegestrant) for the treatment of ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer.

  • First-Ever PROTAC Approval

    VEPPANU is the first and only FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader, validating Arvinas's core technology platform.

  • $50 Million Milestone Payment

    Arvinas will receive a $50.0 million development milestone payment from Pfizer Inc. in connection with the FDA approval.

  • Early Approval

    The approval was received ahead of the FDA-assigned Prescription Drug User Fee Act (PDUFA) date of June 5, 2026.


Analysis · ARVN · Life Sciences

This FDA approval for VEPPANU is a transformative event for Arvinas, marking its first approved medicine and validating its pioneering PROTAC technology. The approval, received ahead of schedule, addresses a significant unmet medical need in ESR1-mutated, ER+/HER2- advanced breast cancer. The $50 million milestone payment from Pfizer provides a substantial cash inflow, further strengthening the company's financial position and supporting its ongoing commercialization strategy with Pfizer and a planned third-party partner. This milestone significantly de-risks the company's pipeline and provides a strong foundation for future growth.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $656.9M. The 52-week trading range was $5.90 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.73 info
Change: -$0.360 (-5%) info
Market Cap: $440.714M info
ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.73 info
Change: -$0.330 (-5%) info
Market Cap: $440.714M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.73 info
Change: -$0.790 (-11%) info
Market Cap: $440.714M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.73 info
Change: -$0.790 (-11%) info
Market Cap: $440.714M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.73 info
Change: -$0.870 (-11%) info
Market Cap: $440.714M info